Why Edwards Lifesciences Corporation’s (EW) Stock Is Up 5.15%
As of Friday, July 24, Edwards Lifesciences Corporation’s EW share price has surged by 5.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Edwards Lifesciences Corporation (EW)
Edwards Lifesciences Corporation EW
$86.07
-0.85
-0.98%
July 31, 2026 4:00:03 PM
EST
Volume: 3,951,928
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NYSE | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Commentary & Analysis
What You Need to Know About Edwards Lifesciences Corporation's Q3 Earnings
Edwards Lifesciences Corporation's fiscal Q3 earnings report was released on Thursday, July 23. Let's dive in to see if (EW) missed or beat analyst's expectations.Michael Rose
Is Edwards Lifesciences Corporation (EW) Overvalued?
We dive into why Edwards Lifesciences Corporation (EW) could be considered overvalued on 2026-07-16, based on AAII’s Value Score and Grade.Jenna Brashear
Why Edwards Lifesciences Corporation’s (EW) Stock Is Up 5.96%
As of Friday, April 24, Edwards Lifesciences Corporation’s EW share price has surged by 5.96%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About Edwards Lifesciences Corporation's Q2 Earnings
Edwards Lifesciences Corporation's fiscal Q2 earnings report was released on Thursday, April 23. Let's dive in to see if (EW) missed or beat analyst's expectations.Rosalio Madrigal
Financial Summary
| Share Statistics | EW | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $49,559.1 | $337.2 | 93% |
|
| Shares Out (Mil) | 580.7 | 41.9 | 90% |
|
| Institutional Ownership | 99.8% | 77.8% | 94% |
|
| Float (Mil) | 574.0 | 34.7 | 87% |
|
| Beta | 0.85 | 0.85 | 50% |
|
| Avg Daily Volume (000s) | 5,702 | 278 | 93% |
|
| Price Change (52-week) |
6.1% | 58.7% | 50% |
|
| Growth | EW | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.7% | 11.8% | 44% |
|
| Net Income (5yr) | 5.4% | (5.8%) | 48% |
|
| EPS (5yr) | 7.1% | 11.4% | 41 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (54.0%) | (16.3%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 23 | 28 | 28 | |
| Current EPS | $0.737 | $2.998 | $3.376 | |
| Month Ago EPS | $0.745 | $3.007 | $3.368 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | $0.745 | $3.006 | $3.363 | |
| Year/Year Chg | 12.2% | 65.6% | 109.4% | |
| Financials | EW | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6,304 | $152 | 78% |
|
| Net Income (TTM) (Mil) | $1,096 | ($10) | 87% |
|
| EPS (TTM) | $1.881 | ($0.500) | 71% |
|
| Operating Cash Flow (TTM) (Mil) | $1,359 | ($2) | 84% |
|
| Net Cash Flow (TTM) (Mil) | ($701) | $1 | 4% |
|
| Long-Term Debt (Q1) (Mil) | $679 | $22 | 62% |
|
| Enterprise Value (Q1) (Mil) | $43,180 | $304 | 91% |
|
| Valuation | EW | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.81 | 2.80 | 77% |
|
| P/E | 46.7 | 31.1 | 82% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 6.9 | 1.9 | 91% |
|
| Ratios | EW | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.8% | 59.1% | 87% |
|
| Net Margin | 15.4% | (7.3%) | 73% |
|
| ROA | 8.3% | (13.7%) | 84% |
|
| ROE | 10.7% | (15.8%) | 60% |
|
| Liabilities to Assets | 22.5% | 44.7% | 15% |
|
| F-Score | 5 | 4 | 51% |
|
Edwards Lifesciences Corporation did not pass any screens on 7/31/2026.
